ARKG ETF — ARK Genomic Revolution ETF

ARK Genomic Revolution ETF (ARKG)

ARKG is an ETF. its expense ratio is 0.75%. Total return is 153.3% over the past 11.8 years, 211.6 points behind SPY at 364.9%.

ARK Genomic Revolution ETF is an actively managed ETF that invests primarily in domestic and foreign companies involved in genomics, gene editing, CRISPR technology, and molecular diagnostics across healthcare, information technology, materials, energy, and consumer discretionary sectors. The fund does not currently distribute income to shareholders and carries an expense ratio of 0.75%. It appeals to growth-oriented investors seeking exposure to genomic innovation rather than current income.

ARKG performance versus SPY

Price and return data through 2026-09-04.

Total return is 153.3% over the past 11.8 years, 211.6 points behind SPY at 364.9%.

ARKG key facts

Issuer

ARK Invest

Asset type

ETF

Asset class

Equity

Inception date

10/31/2014

Expense ratio

0.75%

Distribution frequency

None

Last close

$47.14

NAV

$47.11

Premium / discount

0.06% premium

AUM

$1,997,851,147

Average volume

1445900.0

Last ex-dividend date

12/29/2021 (as of 2021-12-29)

Last payment date

12/31/2021 (as of 2021-12-31)

Beta

2.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: ARK Invest; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARKG risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider ARKG — and who may not

It is a weaker fit for investors who need monthly cash flow (ARKG does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Compare ARKG

ARKG vs similar funds:

• ARKG vs XBI
• ARKG vs HLTH
• ARKG vs HLTH vs XLV

Frequently asked questions

More securities from ARK Invest.